ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

ClinicalTrials.gov ID: NCT06717347

Public ClinicalTrials.gov record NCT06717347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Study identification

NCT ID
NCT06717347
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
1,046 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 26, 2025
Primary completion
Jul 1, 2029
Completion
Mar 28, 2032
Last update posted
May 5, 2026

2025 – 2032

United States locations

U.S. sites
37
U.S. states
21
U.S. cities
35
Facility City State ZIP Site status
Banner MD Anderson Cancer Center ( Site 0165) Gilbert Arizona 85234 Recruiting
Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) Phoenix Arizona 85006 Recruiting
The University of Arizona Cancer Center - North Campus ( Site 0124) Tucson Arizona 85719 Recruiting
Providence Medical Foundation-Oncology ( Site 0168) Fullerton California 92835 Recruiting
Cancer Blood and Specialty Clinic ( Site 0109) Los Alamitos California 90720 Recruiting
Cedars-Sinai Medical Center ( Site 0115) Los Angeles California 90048 Recruiting
Pacific Hematology Oncology Associates ( Site 0131) San Francisco California 94115 Recruiting
Lutheran Hospital - Cancer Centers of Colorado ( Site 0180) Golden Colorado 80401 Recruiting
Clermont Oncology Center ( Site 0182) Clermont Florida 34711 Recruiting
Bioresearch Partner ( Site 0157) Hialeah Florida 33013 Recruiting
Orlando Health Cancer Institute ( Site 0169) Ocoee Florida 34761 Recruiting
Mid Florida Hematology and Oncology Center ( Site 0172) Orange City Florida 32763 Recruiting
Cancer Care Specialists of Illinois ( Site 0152) O'Fallon Illinois 62269 Recruiting
Fort Wayne Medical Oncology and Hematology ( Site 0149) Fort Wayne Indiana 46804 Recruiting
Cotton O'Neil Cancer Center ( Site 0108) Topeka Kansas 66606 Recruiting
University of Kentucky ( Site 0106) Lexington Kentucky 40536 Recruiting
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163) Louisville Kentucky 40207 Recruiting
CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184) Alexandria Louisiana 71301 Recruiting
Karmanos Cancer Institute ( Site 0174) Detroit Michigan 48201 Recruiting
Corewell Health ( Site 0130) Grand Rapids Michigan 49503 Recruiting
The University of Mississippi Medical Center ( Site 0161) Jackson Mississippi 39216 Recruiting
Circuit Clinical - SSM Health Cancer Care DePaul ( Site 0166) Bridgeton Missouri 63044 Recruiting
Truman Medical Center ( Site 0122) Kansas City Missouri 64108 Recruiting
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178) Billings Montana 59102 Recruiting
OptumCare Cancer Care ( Site 0121) Las Vegas Nevada 89102 Recruiting
Comprehensive Cancer Centers of Nevada ( Site 0113) Las Vegas Nevada 89169 Recruiting
New York Oncology Hematology, P.C. ( Site 0129) Albany New York 12206 Recruiting
Icahn School of Medicine at Mount Sinai ( Site 0164) New York New York 10029 Recruiting
Prisma Health - Upstate ( Site 0158) Greenville South Carolina 29605 Recruiting
Sanford Cancer Center ( Site 0143) Sioux Falls South Dakota 57104 Recruiting
The University of Tennessee Medical Center ( Site 0142) Knoxville Tennessee 37920 Recruiting
Center for Oncology and Blood Disorders ( Site 0153) Houston Texas 77030 Recruiting
Houston Methodist Cancer Center ( Site 0154) Houston Texas 77030 Recruiting
University of Virginia Cancer Center ( Site 0138) Charlottesville Virginia 22903 Recruiting
Virginia Cancer Institute ( Site 0148) Richmond Virginia 23229 Recruiting
Blue Ridge Cancer Care ( Site 0132) Roanoke Virginia 24014 Recruiting
SSM Health Dean Medical Group ( Site 0140) Madison Wisconsin 53715 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 159 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06717347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06717347 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →